Liver Cancer (Primary and Metastatic)NCT07587216
Prospective Clinical Database Construction for Liver Cancer Diagnosis and Treatment
An observational study of Liver Cancer (Primary and Metastatic), run by Tongji Hospital at 1 site in China.
Trial summary
This study is a prospective, observational, real-world cohort study. We aim to establish a prospective database in the Department of Hepatobiliary and Pancreatic Surgery, systematically collecting and integrating patients' full-course diagnostic and therapeutic information along with long-term outcomes. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Liver Cancer (Primary and Metastatic)
- What is being tested?
- liver resection and Systemic therapy combined with locoregional interventions
- Type of treatment
- Surgery or procedure
- How many people
- 800 participants
- Where
- 1 siteChina
- Study dates
- 1 Jan 2026to 31 Dec 2029
- How long will I take part?
- 2 Years
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: patients with liver cancer
Who may be able to join
- Male or female aged ≥18 years at the time of signing the informed consent form
- Clinically or histologically confirmed diagnosis of liver cancer
- Recieving treatment and follow-up in Tongji Hospital
Who cannot join
- Refuse participanting in this study
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
China1 site, 1 recruiting
- Recruiting
Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology
Wuhan, Hubei, 430030
Qi Cheng, M.D., 13871459541, chengqi@hust.edu.cn
About this study
This study is a prospective, observational, real-world cohort study. We aim to establish a prospective database in the Department of Hepatobiliary and Pancreatic Surgery, systematically collecting and integrating patients' full-course diagnostic and therapeutic information along with long-term outcomes. This will enable objective evaluation of prognosis and treatment efficacy in real-world clinical practice, while providing a data foundation and evidence support for subsequent optimization of clinical decision-makin
- Conditions
- Liver Cancer (Primary and Metastatic)
- Being tested
- liver resection, Systemic therapy combined with locoregional interventions
- Medical subject headings
- Liver Neoplasms, Neoplasm Metastasis
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
liver resectionProcedure or surgery
Patients undergo liver resection for tumor.
Systemic therapy combined with locoregional interventionsDrug
Patients recieve PD-1 inhibitors combined with targeted drugs and locoregional interventions
| Study group | Role | What they receive |
|---|---|---|
| Liver resection group | Not described Receives: Procedure: liver resection | |
| Non-surgery group | Not described Receives: Drug: Systemic therapy combined with locoregional interventions |
What is being measured
The primary outcome is the main question the study is designed to answer.
overall survival
Measured: From date of treatment until the date of death from any cause, assessed up to 100 months
Secondary outcomes (1)
Incidence of Adverse Events
Measured: Within 30 days following interventions
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted14 May 2026
- Study start1 Jan 2026
- Primary completion31 Dec 2027 (estimated)
- Study completion31 Dec 2029 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Liver Cancer (Primary and Metastatic)Studies of the same condition, open and under way.
- More trials run by Tongji HospitalThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 800 participants (estimated)
- Target duration
- 2 Years
Sponsor and investigators
- Lead sponsor
- Tongji Hospital
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Cheng Qi, Tongji Hospital
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07587216
- Sponsor's protocol ID
- LIC-PRO-2026
- Status last verified
- May 2026
- First submitted
- 8 May 2026
- Last updated
- 4 Jun 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 4 Jun 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Prospective Clinical Database Construction for Liver Cancer Diagnosis and Treatment
- ClinicalTrials.gov ID
- NCT07587216
- Acronym / sponsor ID
- LIC-PRO-2026
- Conditions
- Liver Cancer (Primary and Metastatic)
- Study type
- Observational
- Recruitment status
- Recruiting
- Enrolment
- 800 participants (estimated)
- Lead sponsor
- Tongji HospitalUniversity, hospital or other
- Study start
- 1 Jan 2026 (actual)
- Primary completion
- 31 Dec 2027 (estimated)
- Study completion
- 31 Dec 2029 (estimated)
- First posted
- 14 May 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study is a prospective, observational, real-world cohort study. We aim to establish a prospective database in the Department of Hepatobiliary and Pancreatic Surgery, systematically collecting and integrating patients' full-course diagnostic and therapeutic information along with long-term outcomes. This will enable objective evaluation of prognosis and treatment efficacy in real-world clinical practice, while providing a data foundation and evidence support for subsequent optimization of clinical decision-makin
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Target follow-up
- 2 Years
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Liver resection group | – | Procedure: liver resection |
| Non-surgery group | – | Drug: Systemic therapy combined with locoregional interventions |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- patients with liver cancer
Key inclusion criteria (3 listed)
- Male or female aged ≥18 years at the time of signing the informed consent form
- Clinically or histologically confirmed diagnosis of liver cancer
- Recieving treatment and follow-up in Tongji Hospital
Key exclusion criteria (1 listed)
- Refuse participanting in this study
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| liver resectionPatients undergo liver resection for tumor. | Procedure or surgery | Liver resection group |
| Systemic therapy combined with locoregional interventionsPatients recieve PD-1 inhibitors combined with targeted drugs and locoregional interventions | Drug | Non-surgery group |
Primary outcome
overall survival
Time frame: From date of treatment until the date of death from any cause, assessed up to 100 months
1 secondary outcome
Incidence of Adverse Events
Time frame: Within 30 days following interventions
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 4 Jun 2026.
Related trials for Liver Cancer (Primary and Metastatic)
RecruitingObservational study
Real-world Evaluation of the HistoSonics Edison System for Treatment of Liver Tumors Across Multidisciplinary Users (BOOMBOX: Master Study)
Liver Neoplasms, Primary Liver Cancer
Active, not recruitingPhase 1
Prospective Exploratory Study of FAPi PET/CT With Histopathology Validation in Patients With Various Cancers
Bladder Carcinoma, Cervical Carcinoma
Not yet recruitingObservational study
Immune-Related Adverse Events and Clinical Outcomes of First-Line Immunotherapy in Egyptian Patients With Unresectable Hepatocellular Carcinoma
Hepatocellular Carcinoma, Hepatocellular Carcinoma (HCC)
Not yet recruitingPhase 1
Study of ACC-1898 in Adult Participants With Advanced Solid Tumors
Hepatocellular Carcinoma, Renal Cell Carcinoma
Not yet recruitingObservational study
A Retrospective Registry of Intelliblate DUAL Channel Microwave Ablation
Liver Ablation, Liver Cancer
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Liver Cancer (Primary and Metastatic), run by Tongji Hospital at 1 site in China.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 4 Jun 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in China. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Qi Cheng, M.D. (13871459541, chengqi@hust.edu.cn), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
overall survival (time frame: From date of treatment until the date of death from any cause, assessed up to 100 months). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 4 Jun 2026.